Loading
A phase 3 trial of Datopotamab deruxtecan, Rilvegostomig, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, now recruiting.
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations. ClinicalTrials.gov record last updated 2026-09-23: recruiting. Enrollment is planned at 675 participants. Primary completion is estimated at 2029-12-28. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Datopotamab Deruxtecan, Rilvegostomig, Pembrolizumab. Registered primary measures: Progression-Free Survival (PFS) in TROP2 biomarker positive participants.; Overall Survival (OS) in TROP2 biomarker positive participants..
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, TROP2, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Rilvegostomig, PD-L1-high non-small-cell lung cancer without a driver mutation, AstraZeneca, Pembrolizumab.
Shares Datopotamab deruxtecan, PD-L1-high non-small-cell lung cancer without a driver mutation, TROP2, Small-cell lung cancer.
Shares Rilvegostomig, Datopotamab deruxtecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads).
Shares Datopotamab deruxtecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca.
Shares Datopotamab deruxtecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca.
Shares Datopotamab deruxtecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Datopotamab deruxtecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/